Recent content by average

The Europeans have voted bronchitol down and the company is in the process of appealing the decision. It appears that while bronchitol demonstrated a > 7% increase in FEV1 over 26 weeks against baseline in over 300 patients, that there was a strong placebo responce particularly in adolecents...

The Europeans have voted bronchitol down and the company is in the process of appealing the decision. It appears that while bronchitol demonstrated a > 7% increase in FEV1 over 26 weeks against baseline in over 300 patients, that there was a strong placebo responce particularly in adolecents...

The Europeans have voted bronchitol down and the company is in the process of appealing the decision. It appears that while bronchitol demonstrated a > 7% increase in FEV1 over 26 weeks against baseline in over 300 patients, that there was a strong placebo responce particularly in adolecents...

I suppose what I'm saying is the CFF is a global advocacy body but doesn't appear to openly support new CF therapies unless it has a financial interest in them (ie Vertex, nebulized saline). This mannitol stuff seems to work, so why doesn't the CFF openly apply some advocacy pressure? Agree...

I suppose what I'm saying is the CFF is a global advocacy body but doesn't appear to openly support new CF therapies unless it has a financial interest in them (ie Vertex, nebulized saline). This mannitol stuff seems to work, so why doesn't the CFF openly apply some advocacy pressure? Agree...

I suppose what I'm saying is the CFF is a global advocacy body but doesn't appear to openly support new CF therapies unless it has a financial interest in them (ie Vertex, nebulized saline). This mannitol stuff seems to work, so why doesn't the CFF openly apply some advocacy pressure? Agree...

It appears our friends in Europe have decided that an 6 to 8 percent improvements in lung function (2 clinical trials) in over 600 CF patients over a 12 months is not an sufficient improvement in FEV1 to justify approving the dry powder for marketing approval in Europe.  You have to wonder why...

It appears our friends in Europe have decided that an6 to 8 percent improvements in lung function (2 clinical trials)in over 600 CF patientsover a 12 months is not an sufficient improvementin FEV1 tojustify approving thedry powder for marketing approval in Europe.You have to wonder why...

<p>It appears our friends in Europe have decided that an6 to 8 percent improvements in lung function (2 clinical trials)in over 600 CF patientsover a 12 months is not an sufficient improvementin FEV1 tojustify approving thedry powder for marketing approval in Europe.You have to wonder why...